Update on whether Quizartinib has been launched in China and when it will be launched

Quizartinib is an oral tyrosine kinase inhibitor that targets the FLT3-ITD mutation and is mainly used to treat acute myeloid leukemia (AML). As of now, quizartinib has not been officially approved for marketing in China. Although relevant domestic companies have submitted listing applications, the specific approval and listing time are still in the review process, and there has been no clear official announcement yet. Therefore, domestic patients are temporarily unable to purchase the drug through formal channels.

In the international market, quizartinib has been approved by the United StatesFDA and many other countries for the treatment of AML patients carrying FLT3-ITD mutations. The drug can effectively delay the progression of the disease and improve patient prognosis. There are versions of original drugs in foreign markets, which are more expensive but provide patients with new treatment options. At the same time, clinical research data on quizartinib have gradually become more abundant, confirming its good efficacy and safety.

Since Quizartinib has not yet been launched in China, some patients choose to purchase the drug from abroad. In addition to the expensive original versions, there are also some more economical generic drugs available on the market. For example, the generic version produced by Lucius Pharmaceuticals in Laos includes two specifications: 17.7mg and 26.5mg. Each box sells for about more than 1,000 yuan. The price is relatively affordable and has become an alternative choice for some patients.

It should be reminded that Quizartinib is a prescription drug and must be used under the guidance of a professional doctor. Drugs may cause serious side effects such as prolongation of the QT interval on the electrocardiogram. Patients need to undergo regular cardiac monitoring and related examinations. In addition, drug-drug interactions also require attention, and patients should inform their doctors about all medications they take to ensure the safety and effectiveness of treatment.

Reference materials:https://www.drugs.com/